MedTrace Logo

Mass Balance Study of TS-142 in Healthy Adult Subjects.

NCT04814771 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-02-28

No results posted yet for this study

Summary

To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites of TS-142 after single oral dose of \[14C\] TS-142 in Japanese healthy male subjects.

To assess the safety of single oral dose of \[14C\] TS-142 in Japanese healthy male subjects.

Conditions

  • Healthy Male Subjects

Interventions

DRUG

[14C] TS-142

Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq \[14C\]TS-142 as an oral solution

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taisho Direcoter · Taisho Pharmaceutical Co., Ltd.

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-19
Primary Completion
2021-05-19
Completion
2021-05-19

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04814771 on ClinicalTrials.gov